clinical trial · NCT05155293
Clinical Study to Compare Efficacy and Safety of AVT06 and EU-Eylea (ALVOEYE)
Alvotech Swiss AG·phase3·completed·n = 413
Neovascular (Wet) AMDAVT06 (proposed aflibercept biosimilar)Eylea® (Aflibercept)
brief summary
This is a randomized, double-masked, parallel-group, multicenter, therapeutic equivalence study evaluating the efficacy, safety, and immunogenicity of AVT06 compared with Eylea in subjects with neovascular (wet) AMD.
started
Jun 28, 2022
primary completion
Nov 17, 2023
completion
Sep 23, 2024
last updated
Sep 27, 2024
official title
A Randomized, Double-masked, Parallel-group, Multicenter Clinical Study to Evaluate the Efficacy and Safety of AVT06 Compared With EU-Eylea® in Subjects With Neovascular (Wet) Age-related Macular Degeneration (ALVOEYE)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol